Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis Study by BAMC ...

LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (BDSX) (Nasdaq: BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society ...

Infants born preterm remain vulnerable to numerous health complications, such as respiratory distress syndrome, chronic lung disease, and pulmonary dysfunction. Moreover, extremely low gestational age ...

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies’ (Nasdaq: BIAF; BIAFW) Vice President of Diagnostics, Jennifer Rebeles, Ph.D., was part of a panel of worldwide experts that published the ...

ATLANTA, Georgia — A combination of gene-expression testing (BronchoGen, Allegro Diagnostics) and diagnostic bronchoscopy significantly improves accuracy in the diagnosis of lung cancer, compared with ...

Public health experts from some of the nation's leading research institutions have deployed a large medical trailer to rural parts of the South to test and survey thousands of local residents. The ...

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, ...

Removing race from equations that estimate lung function will shift the categorization of disease severity across patient populations, moving more Black individuals into an advanced disease category, ...

ORACLE test predicts overall cancer survival independent of currently used clinical risk factors, and it has the best predictive power in stage 1 lung cancer. A high ORACLE score is associated with a ...

The Social Security Administration has requested the National Academies of Sciences, Engineering, and Medicine to review the latest published research and science and produce a report addressing best ...

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today the validation and launch of a new method of ...

Credit: Getty Images The road to race-neutral pulmonary function testing has been long and evolving; now, ATS recommends this approach and a Boston hospital offers an implementation model. In July, ...